Positioning
The landscape of peptide information online is dominated by two registers: supplement-store marketing, and gray-market protocol folklore. Neither serves the reader who wants an honest answer.
Our position is editorial. We assume the reader is intelligent, has context, and wants to make their own judgement. We will not condescend, and we will not hype.
Research standards
Every compound page is anchored in primary literature. Phase 2+ clinical data is prioritised where available; peer-reviewed preclinical work supplements where human data is limited. Claims that are mechanism-only — as opposed to outcome-proven — are flagged as such.
We do not make therapeutic claims. We describe research. The distinction matters.
What we don't do
- No hype language. No "game-changing," no "unlock your potential," no exclamation marks in body copy.
- No dosing advice outside a research context. Dose ranges shown reflect published protocols, not personal recommendations.
- No direct-to-consumer sales language. There is no cart, no checkout, and no email capture.
- No clinical consultation. Speak to a qualified practitioner for that — we'll gladly refer you to one.
Research-desk standards — Bangkok.
Thailand Peptides operates a Bangkok-based research desk that sources, verifies, and ships research peptides across Thailand and Southeast Asia. Orders go direct via WhatsApp — no cart, no account, no queue. Response is in English or Thai within business hours (GMT+7, Monday–Saturday).
Primary literature first
Every compound page anchors in peer-reviewed pharmacology. Phase 2+ clinical data is prioritised where available. Preclinical and open-label studies supplement; their limitations are named in plain language, not buried in footnotes.
Mechanism is a starting question
We do not infer efficacy from mechanism alone. A receptor-binding study is not an outcome study. Where the distinction matters, we say so on the compound page, not in a disclaimer.
Dose ranges are research context
Ranges shown on compound pages reflect published protocols — typically IU/week or mg/week windows used in trials. These are not dosing recommendations for any individual. We do not give individualised protocols, and we refer practitioner questions to a licensed clinician.
Quality is lot-level, not brand-level
Every lot undergoes HPLC purity and mass-spec identity verification. Endotoxin and residual-solvent testing on every lot. A certificate of analysis exists for every compound we ship; request it via the research desk for any order.
TH Labs Research Desk.
The TH Labs Research Desk is the editorial group responsible for every research summary, comparison article, and compound brief on peptidesth.com. Articles are written from primary literature, cross-referenced against PubMed-indexed sources, and reviewed before publication.
Our citation discipline: every PMID in every article is verified to resolve at pubmed.ncbi.nlm.nih.gov before publication. Every claim about a compound's mechanism, trial outcome, or safety profile is sourced from peer-reviewed primary literature, not summarised marketing material.
The Research Desk operates as an organisational byline rather than under individual names — a privacy-preserving model that still satisfies E-E-A-T author accountability. Editorial decisions and content standards are owned by the Desk as a whole.
Knowledge Bank first
Every article and review starts from the TH Labs internal Knowledge Bank — a curated set of compound briefs, mechanism notes, and trial extracts maintained by the Research Desk. Articles are written off the brief, not off external blog summaries.
PubMed PMID verification
Every citation in every article is verified to resolve at pubmed.ncbi.nlm.nih.gov before publication. We run a batch verification script (NCBI E-utilities) against the citation list as part of pre-publish CI — fabricated or mis-resolved PMIDs cannot ship.
Pre-publication review by the Research Desk
Articles pass a second pair of eyes inside the Research Desk before going live. The review checks: claim alignment to citations, dose ranges against published protocols, framing of mechanism vs. outcome (we do not infer efficacy from mechanism alone), and tone (no hype, no clinical advice).
Quarterly content refresh
Every article carries an editorial review timestamp (dateReviewed). We re-check the literature on a quarterly cadence — if new trials, retractions, or guideline updates land, the article gets refreshed and the review date rolls forward.
Corrections, citation queries, or editorial feedback: contact@peptidesth.com. Editorial correspondence is handled separately from WhatsApp order channels.
TH Labs Compliance Desk.
A second editorial seam sits inside TH Labs for the highest-risk YMYL content: cardiovascular outcomes summaries, dose-response trial data, and contraindication framing. The Compliance Desk reviews these articles before publication, separately from the Research Desk's primary-literature pass.
The Compliance Desk verdict appears on the byline as "Compliance reviewed by TH Labs Compliance Desk" — surfacing the second pair of eyes that handled the YMYL-sensitive material. Same organisational-byline privacy posture as the Research Desk: a desk-level accountability frame, not individual names.
Every lot, every compound.
Certificate of analysis available on request per compound. Contact the research desk for lot-specific documentation.
Open a line.
WhatsApp. Research desk, GMT+7.